In a proof-of-concept study, solid phase synthesis allowed the rapid generation of a small molecule drug conjugate in which the glutamate carboxypeptidase II (GCPII) targeting small molecule DUPA was conjugated to the alkylating subunit of the potent cytotoxin duocarmycin SA. The targeted SMDC contained a cathepsin B cleavable linker, which was shown to be active and selective against cathepsin B over-expressing and GCPII-expressing tumour cell lines
The innovative development and success of monoclonal antibodies (mAbs) was essential in the race to ...
The development of protein-protein interaction (PPI) inhibitors with therapeutic value is of increas...
yesCC-1065, the duocarmycins and yatakemycin are members of a family of ultrapotent antitumour antib...
Solid phase synthesis allowed the rapid generation of a peptide-drug conjugate. A peptide targeting ...
The CC-1065 and duocarmycin family of compounds are ultrapotent antitumour antibiotics which demonst...
Self-assembling ultrashort peptides from aliphatic amino acids were functionalized with platinum ant...
YesThe duocarmycins are potent antitumour agents with potential in the development of antibody drug...
The family is characterised by a common spirocyclopropylcyclohexadienone pharmacophore. This unusual...
Peptide-Drug Conjugates (PDCs) and Antibody-Drug Conjugates (ADCs) are compounds that aim to specifi...
This project describes the development of a new antitumor therapeutic platform that combines the ben...
YesA library of duocarmycin bioprecursors based on the CPI and CBI scaffolds was synthesized and use...
The delivery of cytotoxicity to specific cells was recognized to be the key to the effective, chemic...
Antibody-drug conjugates are a very promising class of new anticancer agents, but the use of small-m...
149 pagesMy graduate research focuses on the development of small molecule probes or inhibitors that...
Antibody drug conjugates (ADCs), which are obtained by coupling a potent cytotoxic agent to a monocl...
The innovative development and success of monoclonal antibodies (mAbs) was essential in the race to ...
The development of protein-protein interaction (PPI) inhibitors with therapeutic value is of increas...
yesCC-1065, the duocarmycins and yatakemycin are members of a family of ultrapotent antitumour antib...
Solid phase synthesis allowed the rapid generation of a peptide-drug conjugate. A peptide targeting ...
The CC-1065 and duocarmycin family of compounds are ultrapotent antitumour antibiotics which demonst...
Self-assembling ultrashort peptides from aliphatic amino acids were functionalized with platinum ant...
YesThe duocarmycins are potent antitumour agents with potential in the development of antibody drug...
The family is characterised by a common spirocyclopropylcyclohexadienone pharmacophore. This unusual...
Peptide-Drug Conjugates (PDCs) and Antibody-Drug Conjugates (ADCs) are compounds that aim to specifi...
This project describes the development of a new antitumor therapeutic platform that combines the ben...
YesA library of duocarmycin bioprecursors based on the CPI and CBI scaffolds was synthesized and use...
The delivery of cytotoxicity to specific cells was recognized to be the key to the effective, chemic...
Antibody-drug conjugates are a very promising class of new anticancer agents, but the use of small-m...
149 pagesMy graduate research focuses on the development of small molecule probes or inhibitors that...
Antibody drug conjugates (ADCs), which are obtained by coupling a potent cytotoxic agent to a monocl...
The innovative development and success of monoclonal antibodies (mAbs) was essential in the race to ...
The development of protein-protein interaction (PPI) inhibitors with therapeutic value is of increas...
yesCC-1065, the duocarmycins and yatakemycin are members of a family of ultrapotent antitumour antib...